Liposomes : a promising carrier for respiratory syncytial virus therapeutics

Tools

Joshi, Sameer and Bawage, Swapnil and Tiwari, Pooja and Kirby, Daniel and Perrie, Yvonne and Dennis, Vida and Singh, Shree R. (2019) Liposomes : a promising carrier for respiratory syncytial virus therapeutics. Expert Opinion on Drug Delivery, 16 (9). pp. 969-980. ISSN 1742-5247 (https://doi.org/10.1080/17425247.2019.1652268)

[thumbnail of Joshi-etal-EODR-2019-Liposomes-a-promising-carrier-for-respiratory-syncytial-virus-therapeutics]
Preview
 Text. Filename: Joshi_etal_EODR_2019_Liposomes_a_promising_carrier_for_respiratory_syncytial_virus_therapeutics.pdf
Accepted Author Manuscript
Download (1MB)| Preview

Abstract

Introduction: Human respiratory syncytial virus (RSV) is a common respiratory virus that causes severe lower respiratory tract infection in infants, children and aged adults. Currently, there is no active prophylaxis present in the market for RSV infection; however, there are over a dozen compounds being tested in the laboratory as well as clinical trials. To increase the efficiency and safety of these therapeutics, there is a need for delivery vehicles. Areas covered: Liposomes can be used for delivering anti-RSV agents with the advantage of modulating and eliciting the desired adjuvant effect by the different combination of lipids. This review discusses the promising application of liposome for anti-RSV therapeutics. Expert opinion: Liposomes are attracting attention for delivery of pulmonary therapeutics, since they offer compatibility for delivering drugs, vaccines and other therapeutic molecules. Variation in liposome size and composition gives flexibility for the amount and number of deliverables, whilst targeted delivery with the capability for immunomodulation makes liposomes a promising candidate for RSV therapeutic applications.

CORE (COnnecting REpositories)